Mechanisms of lymphangiogenesis Sample Clauses

Mechanisms of lymphangiogenesis. The VEGF-C/D and VEGFR3 pathway is the central pathway in lymphangiogenesis (144). As mentioned previously, VEGFC/VEGFR3 signalling is essential for lymphatic sprouting from the cardinal vein in embryogenesis (145). Activation of VEGFR3 leads to phosphorylation of the serine kinases AKT and extracellular signal-related kinase (ERK), which promotes proliferation, migration and survival of LECs (146). PI3K, which is upstream of AKT, interacts directly with VEGFR3 and promotes tube formation (147). Interestingly, defects in the PI3K pathway affect lymphatic vasculature only and have no effect on blood vessels; suggesting that AKT functions distinctively in LECs. The congenital primary lymphedema condition Xxxxxx’x disease is caused by missense mutations in the tyrosine kinase domain of VEGFR3 (105). The VEGF and VEGFR2 pathway plays less of a role in lymphangiogenesis than the VEGFC/VEGFR3 pathway. Specific activation of this pathway causes vessel enlargement but does not initiate sprouting (148), and deletion of the VEGFR2 gene in LECs does not affect lymphatic vessel function in embryogenesis and adult mice (149). There are also data to show that the Notch pathway plays a role in VEGF/VEGFR2- induced lymphangiogenesis. It was found that lymphangiogenesis occurring via this pathway was enhanced when the Notch pathway was inhibited; and this was not seen in VEGFC/VEGFR3-induced lymphangiogenesis (150). The collagen and calcium-binding EGF domain-containing protein 1 (CCBE1) is a highly conserved lymphagiogenic factor, and the result of deletion of this protein is similar to VEGFC deletion, with embryos not forming lymphatic vessels (151). Mutations in the CCBE1 gene in humans cause primary lymphedema in Henneken’s syndrome (152). Exogenous CCBE1 has little effect on inducing lymphangiogenesis, but seems to interact with the VEGFC pathway (153). Semaphorins and neuropilins have traditionally been described for their pivotal role in the central nervous system; however, they are now becoming recognised in the field of lymphangiogenesis. Neuropilin (NRP) 2 is a co-receptor for VEGFC and binding causes co-internalization of the two receptors which enhances VEGFC signalling (154). NRP2- deficient mice have normal blood vasculature but decreased density of lymphatic capillaries in tissue (155). The NRP1 ligand semaphorin (SEMA) 3A is highly expressed in LECs and is particularly involved in lymphatic valve formation, where it has been shown to facilitate the migratio...
AutoNDA by SimpleDocs

Related to Mechanisms of lymphangiogenesis

  • Research, Science and Technology Cooperation 1. The aims of cooperation in research, science and technology, carried out in the mutual interest of the Parties and in compliance with their policies, will be: (a) to build on existing agreements already in place for cooperation on research, science and technology; (b) to encourage, where appropriate, government agencies, research institutions, universities, private companies and other research organizations in the Parties to conclude direct arrangements in support of cooperative activities, programs or projects within the framework of this Agreement, specially related to trade and commerce; and (c) to focus cooperative activities towards sectors where mutual and complementary interests exist, with special emphasis on information and communication technologies and software development to facilitate trade between the Parties. 2. The Parties will encourage and facilitate, as appropriate, the following activities including, but not limited to:

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Vaccination and Inoculation (a) The Employer agrees to take all reasonable precautions, including in-service seminars, to limit the spread of infectious diseases among employees.

  • Rhytidectomy Scar revision, regardless of symptoms. • Sclerotherapy for spider veins. • Skin tag removal. • Subcutaneous injection of filling material. • Suction assisted Lipectomy. • Tattooing or tattoo removal except tattooing of the nipple/areola related to a mastectomy. • Treatment of vitiligo. • Standby services of an assistant surgeon or anesthesiologist. • Orthodontic services related to orthognathic surgery. • Cosmetic procedures when performed primarily: o to refine or reshape body structures or dental structures that are not functionally impaired; o to improve appearance or self-esteem; or o for other psychological, psychiatric or emotional reasons. • Drugs, biological products, hospital charges, pathology, radiology fees and charges for surgeons, assistant surgeons, attending physicians and any other incidental services, which are related to cosmetic surgery.

  • Joint Network Implementation and Grooming Process Upon request of either Party, the Parties shall jointly develop an implementation and grooming process (the “Joint Grooming Process” or “Joint Process”) which may define and detail, inter alia:

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • COVID-19 Protocols Contractor will abide by all applicable COVID-19 protocols set forth in the District’s Reopening and COVID-19 Mitigation Plan and the safety guidelines for COVID-19 prevention established by the California Department of Public Health and the Ventura County Department of Public Health.

  • Probes Network hosts used to perform (DNS, EPP, etc.) tests (see below) that are located at various global locations.

  • Protocols Each party hereby agrees that the inclusion of additional protocols may be required to make this Agreement specific. All such protocols shall be negotiated, determined and agreed upon by both parties hereto.

  • Research Use The Requester agrees that if access is approved, (1) the PI named in the DAR and (2) those named in the “Senior/Key Person Profile” section of the DAR, including the Information Technology Director and any trainee, employee, or contractor1 working on the proposed research project under the direct oversight of these individuals, shall become Approved Users of the requested dataset(s). Research use will occur solely in connection with the approved research project described in the DAR, which includes a 1-2 paragraph description of the proposed research (i.e., a Research Use Statement). Investigators interested in using Cloud Computing for data storage and analysis must request permission to use Cloud Computing in the DAR and identify the Cloud Service Provider (CSP) or providers and/or Private Cloud System (PCS) that they propose to use. They must also submit a Cloud Computing Use Statement as part of the DAR that describes the type of service and how it will be used to carry out the proposed research as described in the Research Use Statement. If the Approved Users plan to collaborate with investigators outside the Requester, the investigators at each external site must submit an independent DAR using the same project title and Research Use Statement, and if using the cloud, Cloud Computing Use Statement. New uses of these data outside those described in the DAR will require submission of a new DAR; modifications to the research project will require submission of an amendment to this application (e.g., adding or deleting Requester Collaborators from the Requester, adding datasets to an approved project). Access to the requested dataset(s) is granted for a period of one (1) year, with the option to renew access or close-out a project at the end of that year. Submitting Investigator(s), or their collaborators, who provided the data or samples used to generate controlled-access datasets subject to the NIH GDS Policy and who have Institutional Review Board (IRB) approval and who meet any other study specific terms of access, are exempt from the limitation on the scope of the research use as defined in the DAR.

Time is Money Join Law Insider Premium to draft better contracts faster.